Pracinostat

Drug Profile

Pracinostat

Alternative Names: SB-939

Latest Information Update: 21 Dec 2016

Price : $50

At a glance

  • Originator S*BIO
  • Developer MEI Pharma; S*BIO; University of Texas M. D. Anderson Cancer Center
  • Class Acrylamides; Antineoplastics; Hydroxamic acids; Small molecules
  • Mechanism of Action Histone deacetylase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acute myeloid leukaemia
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Acute myeloid leukaemia; Myelodysplastic syndromes; Myelofibrosis

Most Recent Events

  • 05 Dec 2016 Final efficacy and adverse events data from a phase II trial in Acute myeloid leukaemia (Combination therapy, In the elderly, Newly diagnosed) presented at the 58th Annual Meeting and Exposition of the American Society of Hematology (ASH-Hem-2016)
  • 08 Aug 2016 Pracinostat licensed to Helsinn worldwide
  • 08 Aug 2016 MEI Pharma and Helsinn plan a clinical trial for Myelodysplastic syndrome in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top